» Articles » PMID: 39654725

Targeting Pivotal Amino Acids Metabolism for Treatment of Leukemia

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 Dec 10
PMID 39654725
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic reprogramming is a crucial characteristic of cancer, allowing cancer cells to acquire metabolic properties that support their survival, immune evasion, and uncontrolled proliferation. Consequently, targeting cancer metabolism has become an essential therapeutic strategy. Abnormal amino acid metabolism is not only a key aspect of metabolic reprogramming but also plays a significant role in chemotherapy resistance and immune evasion, particularly in leukemia. Changes in amino acid metabolism in tumor cells are typically driven by a combination of signaling pathways and transcription factors. Current approaches to targeting amino acid metabolism in leukemia include inhibiting amino acid transporters, blocking amino acid biosynthesis, and depleting specific amino acids to induce apoptosis in leukemic cells. Different types of leukemic cells rely on the exogenous supply of specific amino acids, such as asparagine, glutamine, arginine, and tryptophan. Therefore, disrupting the supply of these amino acids may represent a vulnerability in leukemia. This review focuses on the pivotal role of amino acids in leukemia metabolism, their impact on leukemic stem cells, and their therapeutic potential.

Citing Articles

Tyrosine Kinase Inhibitor Therapy Enhances Stem Cells Profile and May Contribute to Survival of Chronic Myeloid Leukemiastem Cells.

Rocco S, Maglione A, Schiavo V, Ferrando A, Fava C, Cilloni D J Clin Med. 2025; 14(2).

PMID: 39860398 PMC: 11765529. DOI: 10.3390/jcm14020392.


Probing the Effects of Multisite Mutations in the Lipoic Acid Region of the BCOADC-E2 Protein.

Wang J, Yang M, Wei H, Miao W, Li S, Gao X Int J Mol Sci. 2025; 25(24.

PMID: 39769438 PMC: 11678370. DOI: 10.3390/ijms252413677.

References
1.
Ni Y, Schwaneberg U, Sun Z . Arginine deiminase, a potential anti-tumor drug. Cancer Lett. 2008; 261(1):1-11. DOI: 10.1016/j.canlet.2007.11.038. View

2.
Lagadinou E, Sach A, Callahan K, Rossi R, Neering S, Minhajuddin M . BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329-41. PMC: 3595363. DOI: 10.1016/j.stem.2012.12.013. View

3.
Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

4.
Viale A, Pettazzoni P, Lyssiotis C, Ying H, Sanchez N, Marchesini M . Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014; 514(7524):628-32. PMC: 4376130. DOI: 10.1038/nature13611. View

5.
Ortega J, Nesbit Jr M, Donaldson M, Hittle R, Weiner J, Karon M . L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res. 1977; 37(2):535-40. View